Pfizer (NYSE:PFE) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Pfizer (NYSE:PFE) in a research report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $75.00 price objective on the biopharmaceutical company’s stock.

Several other research firms have also commented on PFE. Jefferies Financial Group dropped their price target on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. Credit Suisse Group cut Pfizer from an outperform rating to a neutral rating and lowered their price target for the stock from $47.00 to $40.00 in a research report on Thursday, June 29th. Daiwa Capital Markets cut shares of Pfizer from an outperform rating to a neutral rating and set a $38.00 price objective for the company. in a research note on Thursday, May 11th. Morgan Stanley lowered their price target on shares of Pfizer from $42.00 to $40.00 and set an equal weight rating on the stock in a report on Wednesday, August 2nd. Finally, StockNews.com assumed coverage on Pfizer in a research note on Thursday, August 17th. They issued a hold rating on the stock. Twelve research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $46.35.

Pfizer Stock Performance

NYSE:PFE opened at $35.38 on Tuesday. The firm’s fifty day simple moving average is $36.13 and its 200 day simple moving average is $38.38. Pfizer has a twelve month low of $34.65 and a twelve month high of $54.93. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The stock has a market cap of $199.75 billion, a P/E ratio of 9.41, a price-to-earnings-growth ratio of 1.19 and a beta of 0.59.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The company’s quarterly revenue was down 54.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.04 EPS. As a group, research analysts predict that Pfizer will post 3.33 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were paid a $0.41 dividend. The ex-dividend date was Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.64%. Pfizer’s dividend payout ratio is currently 43.62%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PFE. 25 LLC purchased a new stake in Pfizer in the 1st quarter worth approximately $25,000. Worth Asset Management LLC purchased a new position in shares of Pfizer during the 1st quarter worth about $29,000. Freedom Wealth Alliance LLC purchased a new position in Pfizer during the fourth quarter worth approximately $35,000. Macroview Investment Management LLC boosted its holdings in shares of Pfizer by 70.0% in the 1st quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 396 shares during the last quarter. Finally, Steward Financial Group LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own 68.05% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.